These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18565245)

  • 1. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice.
    Haibel H; Song IH; Rudwaleit M; Listing J; Hildemann S; Sieper J
    Clin Exp Rheumatol; 2008; 26(2):247-52. PubMed ID: 18565245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12].
    Haibel H; Niewerth M; Brandt J; Rudwaleit M; Listing J; Sieper J; Braun J
    Z Rheumatol; 2004 Oct; 63(5):393-401. PubMed ID: 15517300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
    Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
    Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
    Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial.
    Haibel H; Brandt HC; Song IH; Brandt A; Listing J; Rudwaleit M; Sieper J
    Ann Rheum Dis; 2007 Mar; 66(3):419-21. PubMed ID: 16901959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A short-term efficacy and safety study of infliximab in active ankylosing spondylitis].
    Huang F; Zhang LY; Zhang JL; Zhang FC; Liang DF; Deng XH; Guo JH; Zhu J; Zhao W; Li XF; Hou Y
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):122-6. PubMed ID: 16624120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab treatment in ankylosing spondylitis: an observational study.
    Nikas SN; Alamanos Y; Voulgari PV; Pliakou XI; Papadopoulos CG; Drosos AA
    Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks.
    Haibel H; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2005 Feb; 64(2):296-8. PubMed ID: 15208175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of Life and Clinical Response to On-Demand Maintenance Doses of Infliximab in Patients With Ankylosing Spondylitis.
    Sengupta S; Ray J; Ghosh B
    J Clin Rheumatol; 2015 Oct; 21(7):355-8. PubMed ID: 26398462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2005 Feb; 64(2):229-34. PubMed ID: 15388511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six months open label trial of leflunomide in active ankylosing spondylitis.
    Haibel H; Rudwaleit M; Braun J; Sieper J
    Ann Rheum Dis; 2005 Jan; 64(1):124-6. PubMed ID: 15608310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Golder W; Gromnica-Ihle E; Kellner H; Krause A; Schneider M; Sörensen H; Zeidler H; Thriene W; Sieper J
    Lancet; 2002 Apr; 359(9313):1187-93. PubMed ID: 11955536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.
    Barkham N; Keen HI; Coates LC; O'Connor P; Hensor E; Fraser AD; Cawkwell LS; Bennett A; McGonagle D; Emery P
    Arthritis Rheum; 2009 Apr; 60(4):946-54. PubMed ID: 19333933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.